TNFSF4 antibody (Middle Region)
Quick Overview for TNFSF4 antibody (Middle Region) (ABIN929124)
Target
See all TNFSF4 AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- Middle Region
-
Purification
- Purified
-
Immunogen
- TNFSF4 antibody was raised in rabbit using the middle region of TNFSF4 as the immunogen
-
-
-
-
Application Notes
-
WB: 0.2-1 µg/mL
Optimal conditions should be determined by the investigator. -
Comment
-
TNFSF4 Blocking Peptide, (ABIN5616713), is also available for use as a blocking control in assays to test for specificity of this TNFSF4 antibody
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Concentration
- Lot specific
-
Buffer
- Lyophilized powder. Add 50 µL of distilled water. Final antibody concentration is 1 mg/mL in PBS buffer.
-
Handling Advice
- Avoid repeated freeze/thaw cycles.
-
Storage
- 4 °C/-20 °C
-
Storage Comment
- Store at 4 °C, following reconstitution, aliquot and store at -20 °C.
-
-
- TNFSF4 (Tumor Necrosis Factor (Ligand) Superfamily, Member 4 (TNFSF4))
-
Alternative Name
- TNFSF4
-
Background
- The protein encoded by this gene is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This cytokine is a ligand for receptor TNFRSF4/OX4. It is found to be involved in T cell antigen-presenting cell (APC) interactions. In surface Ig- and CD40-stimulated B cells, this cytokine along with CD70 has been shown to provide CD28-independent costimulatory signals to T cells. This protein and its receptor are reported to directly mediate adhesion of activated T cells to vascular endothelial cells. Synonyms: Polyclonal TNFSF4 antibody, Anti-TNFSF4 antibody, tumor necrosis factor, ligand superfamily, member 4 antibody, CD134L antibody, CD252 antibody, GP34 antibody, OX-40L antibody, OX4OL antibody, TXGP1 antibody.
-
Pathways
- Cellular Response to Molecule of Bacterial Origin, Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Production of Molecular Mediator of Immune Response, Activated T Cell Proliferation, Cancer Immune Checkpoints
Target
-